Skip to main content
SpringerLink
Log in

Anti-FR Antibody Generation and Engineering: Development of New Therapeutic Tools

  • Chapter
  • First Online:
Targeted Drug Strategies for Cancer and Inflammation

  • 883 Accesses

Abstract

The discovery of the methodology to raise mouse monoclonal antibodies (mAbs) represents a milestone in the history of medicine and has opened the way to antibody therapy development. In the oncologic field, antibody-based therapy seems an attractive strategy for those tumors, such as epithelial ovarian cancer and glioblastoma, for which the existing treatment options are still not sufficient. Initial clinical trials with mouse mAbs enlighten, as major limitations, their xenogenic origin and their dimension. Thus, in order to optimize mAb clinical therapeutic applications, genetic engineering was developed to: (1) generate chimeric, humanized, and human mAbs starting from mouse mAbs; (2) reshape antibody format; (3) increase antibody efficacy. The history of anti-human folate receptor (FR)α mAb generation and its modification paralleled that of genetic engineering of mAbs. At least three anti-FRα mAbs (MOv18, MOv19, and LK26) and their derivatives have reached advanced levels of development. In this chapter, the most relevant preclinical and clinical results obtained with them are widely discussed. Also, published data related to anti-FRβ mAb are reported. Full exploitation of the described anti-FRα antibody-based reagents, however, awaits the confirmation of promising drug safety and clinical efficacy from well-designed, randomized clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alberti S, Miotti S, Fornaro M, Mantovani L, Walter S, Canevari S, Ménard S, Colnaghi MI (1990) The Ca-MOv18 molecule, a cell-surface marker of human ovarian carcinomas, is anchored to the cell membrane by phosphatidylinositol. Biochem Biophys Res Commun 171:1051–1055

    Article  PubMed  CAS  Google Scholar 

  • Alvarez-Vallina L (2001) Genetic approaches for antigen-selective cell therapy. Curr Gene Ther 1:385–397

    Article  PubMed  CAS  Google Scholar 

  • Andersson H, Lindegren S, Back T, Jacobsson L, Leser G, Horvath G (2000) The curative and palliative potential of the monoclonal antibody MOv18 labelled with 211At in nude mice with intraperitoneally growing ovarian cancer xenografts – a long-term study. Acta Oncol 39:741–745

    Article  PubMed  CAS  Google Scholar 

  • Berrocal-Zaragoza MI, Fernandez-Ballart JD, Murphy MM, Cavalle-Busquets P, Sequeira JM, Quadros EV (2009a) Association between blocking folate receptor autoantibodies and subfertility. Fertil Steril 91:1518–1521

    Article  PubMed  Google Scholar 

  • Berrocal-Zaragoza MI, Murphy MM, Ceruelo S, Quadros EV, Sequeira JM, Fernandez-Ballart JD (2009b) High milk consumers have an increased risk of folate receptor blocking autoantibody production but this does not affect folate status in Spanish men and women. J Nutr 139:1037–1041

    Article  PubMed  CAS  Google Scholar 

  • Bille C, Pedersen DA, Andersen AM, Mansilla MA, Murray JC, Christensen K, Ballard JL, Gorman EB, Cabrera RM, Finnell RH (2009) Autoantibodies to folate receptor alpha during early pregnancy and risk of oral clefts in Denmark. Pediatr Res 67(3):274–9

    Article  Google Scholar 

  • Bindon CI, Hale G, Bruggemann M, Waldmann H (1988) Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med 168:127–142

    Article  PubMed  CAS  Google Scholar 

  • Bottero F, Tomassetti A, Canevari S, Miotti S, Ménard S, Colnaghi MI (1993) Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res 53:5791–5796

    PubMed  CAS  Google Scholar 

  • Boulianne GL, Hozumi N, Shulman MJ (1984) Production of functional chimaeric mouse/human antibody. Nature 312:643–646

    Article  PubMed  CAS  Google Scholar 

  • Brown JM, Neuper C, Clayton A, Mariani A, Konecny G, Thomas MB, Keeney G, Hartmann L, Podratz KC (2008) Rationale for folate receptor alpha targeted therapy in “high risk” endometrial carcinomas. Int J Cancer 123:1699–1703

    Article  Google Scholar 

  • Buist MR, Kenemans P, Van Kamp GJ, Haisma HJ (1995) Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays. Cancer Immunol Immunother 40:24–30

    Article  PubMed  CAS  Google Scholar 

  • Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ, Ludwig DL (2003) A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63:8912–8921

    PubMed  CAS  Google Scholar 

  • Cabrera RM, Shaw GM, Ballard JL, Carmichael SL, Yang W, Lammer EJ, Finnell RH (2008) Autoantibodies to folate receptor during pregnancy and neural tube defect risk. J Reprod Immunol 79:85–92

    Article  PubMed  CAS  Google Scholar 

  • Canevari S, Mezzanzanica D, Mazzoni A, Negri DRM, Ramakrishna V, Bolhuis RLH, Colnaghi MI, Bolis G (1995a) Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions. J Hematother 4:423–427

    Article  PubMed  CAS  Google Scholar 

  • Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, Di Re E, Eggermont AMM, Goey SH, Gratama JW, Lamers CHJ, Nooy MA, Parmiani G, Raspagliesi F, Ravagnani F, Scarfone G, Trimbos JB, Warnaar SO, Bolhuis RLH (1995b) Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T-lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 87:1463–1469

    Article  PubMed  CAS  Google Scholar 

  • Canevari S, Biocca S, Figini M (2002) Re: blocking oncogenic Ras signalling for cancer therapy. J Natl Cancer Inst 94:1031–1032

    Article  PubMed  Google Scholar 

  • Carter TM, Brooks SA (2006) Detection of aberrant glycosylation in breast cancer using lectin histochemistry. Methods Mol Med 120:201–216

    PubMed  CAS  Google Scholar 

  • Casalini P, Mezzanzanica D, Canevari S, Della Torre G, Miotti S, Colnaghi MI, Matzku S (1991) Use of combination of monoclonal antibodies directed against three distinct epitopes of a tumor-associated antigen: analysis of cell binding and internalization. Int J Cancer 48:284–290

    Article  PubMed  CAS  Google Scholar 

  • Clackson T, Hoogenboom HR, Griffiths AD, Winter G (1991) Making antibody fragments using phage display libraries. Nature 352:624–628

    Article  PubMed  CAS  Google Scholar 

  • Coliva A, Zacchetti A, Luison E, Tomassetti A, Bongarzone I, Seregni E, Bombardieri E, Martin F, Giussani A, Figini M, Canevari S (2005) 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunol Immunother 54:1200–1213

    Article  PubMed  CAS  Google Scholar 

  • Coney LR, Tomassetti A, Carayannopoulos L, Frasca V, Kamen BA, Colnaghi MI, Zurawski VR Jr (1991) Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res 51:6125–6132

    PubMed  CAS  Google Scholar 

  • Coney LR, Mezzanzanica D, Sanborn D, Casalini P, Colnaghi MI, Zurawski VR Jr (1994) Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing. Cancer Res 54:2448–2455

    PubMed  CAS  Google Scholar 

  • Crippa F, Buraggi GL, Di Re E, Gasparini M, Seregni E, Canevari S, Gadina M, Presti M, Marini A, Seccamani E (1991) Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody. Eur J Cancer 27:724–729

    Article  PubMed  CAS  Google Scholar 

  • Crippa F, Bolis G, Seregni E, Gavoni N, Bombardieri E, Scarfone G, Ferrari C, Buraggi GL (1995) Single dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody 131I-MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer 31A:686–690

    Article  PubMed  CAS  Google Scholar 

  • DeNardo GL, Bradt BM, Mirick GR, DeNardo SJ (2003) Human antiglobulin response to foreign antibodies: therapeutic benefit? Cancer Immunol Immunother 52:309–316

    PubMed  CAS  Google Scholar 

  • Dorig RE, Marcil A, Chopra A, Richardson CD (1993) The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75:295–305

    Article  PubMed  CAS  Google Scholar 

  • Dyer MJS, Hale G, Hayhoe FGJ, Waldmann H (1989) Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 73:1431–1439

    PubMed  CAS  Google Scholar 

  • Ebel W, Routhier EL, Foley B, Jacob S, McDonough JM, Patel RK, Turchin HA, Chao Q, Kline JB, Old LJ, Phillips MD, Nicolaides NC, Sass PM, Grasso L (2007) Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 7:6

    PubMed  Google Scholar 

  • Ferrini S, Cambiaggi A, Cantoni C, Canevari S, Mezzanzanica D, Colnaghi MI, Moretta L (1992) Targeting of T or NK lymphocytes against tumor cells by bispecific monoclonal antibodies: role of different triggering molecules. Int J Cancer 7:15–18

    CAS  Google Scholar 

  • Figini M, Marks JD, Winter G, Griffiths AD (1994) In vitro assembly of repertoires of antibody chains on the surface of phage by renaturation. J Mol Biol 239:68–78

    Article  PubMed  CAS  Google Scholar 

  • Figini M, Obici L, Mezzanzanica D, Griffiths AD, Colnaghi MI, Winter G, Canevari S (1998) Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection. Cancer Res 58:991–996

    PubMed  CAS  Google Scholar 

  • Figini M, Ferri R, Mezzanzanica D, Bagnoli M, Luison E, Miotti S, Canevari S (2003) Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti-folate receptor antibodies. Gene Ther 10:1018–1025

    Article  PubMed  CAS  Google Scholar 

  • Figini M, Martin F, Ferri R, Luison E, Ripamonti E, Zacchetti A, Mortarino M, Di Cioccio V, Maurizi G, Allegretti M, Canevari S (2009) Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor. Cancer Immunol Immunother 58:531–546

    Article  PubMed  CAS  Google Scholar 

  • Gadina M, Canevari S, Ripamonti M, Mariani M, Colnaghi MI (1991) Preclinical pharmacokinetics and localization studies of the radioiodinated anti-ovarian carcinoma MAb MOv18. Nucl Med Biol 18:403–408

    CAS  Google Scholar 

  • Garin-Chesa P, Campbell I, Saigo PE, Lewis JL Jr, Old LJ, Rettig WJ (1993) Trophoblast and ovarian cancer antigen LK26: sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol 142:557–567

    PubMed  CAS  Google Scholar 

  • Gould HJ, Mackay GA, Karagiannis SN, O’Toole CM, Marsh PJ, Daniel BE, Coney LR, Zurawski VR Jr, Joseph M, Capron M, Gilbert M, Murphy GF, Korngold R (1999) Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. Eur J Immunol 29:3527–3537

    Article  PubMed  CAS  Google Scholar 

  • Halin C, Gafner V, Villani ME, Borsi L, Berndt A, Kosmehl H, Zardi L, Neri D (2003) Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res 63:3202–3210

    PubMed  CAS  Google Scholar 

  • Hartmann LC, Keeney GL, Lingle WL, Christianson TJ, Varghese B, Hillman D, Oberg AL, Low PS (2007) Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer 121:938–942

    Article  PubMed  CAS  Google Scholar 

  • Hasegawa K, Nakamura T, Harvey M, Ikeda Y, Oberg A, Figini M, Canevari S, Hartmann LC, Peng KW (2006) The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res 12:6170–6178

    Article  PubMed  CAS  Google Scholar 

  • Hawkins RE, Russell SJ, Winter G (1992) Selection of phage antibodies by binding affinity: mimicking affinity maturation. J Mol Biol 226:889–896

    Article  PubMed  CAS  Google Scholar 

  • Hoogenboom HR (2005) Selecting and screening recombinant antibody libraries. Nat Biotechnol 23:1105–1116

    Article  PubMed  CAS  Google Scholar 

  • Hwu P, Yang JC, Cowherd R, Treisman J, Shafer GE, Eshhar Z, Rosenberg SA (1995) In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 55:3369–3373

    PubMed  CAS  Google Scholar 

  • Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249

    Article  PubMed  Google Scholar 

  • Jespers L, Schon O, James LC, Veprintsev D, Winter G (2004) Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold. J Mol Biol 337:893–903

    Article  PubMed  CAS  Google Scholar 

  • Johnson EE, Lum HD, Rakhmilevich AL, Schmidt BE, Furlong M, Buhtoiarov IN, Hank JA, Raubitschek A, Colcher D, Reisfeld RA, Gillies SD, Sondel PM (2008) Intratumoral immunocytokine treatment results in enhanced antitumor effects. Cancer Immunol Immunother 57:1891–1902

    Article  PubMed  CAS  Google Scholar 

  • Kalli KR (2007) MORAb-003, a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer. Curr Opin Investig Drugs 8:1067–1073

    PubMed  CAS  Google Scholar 

  • Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, Shitara K, Satoh M (2007) Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 17:104–118

    Article  PubMed  CAS  Google Scholar 

  • Kang AS, Barbas CF, Janda KD, Benkovic SJ, Lerner RA (1991) Linkage of recognition and replication functions by assembling combinational antibody Fab libraries along phage surfaces. Proc Natl Acad Sci USA 88:4363–4366

    Article  PubMed  CAS  Google Scholar 

  • Karagiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, Thompson RG, Durham SR, Schwartz LB, Balkwill FR, Gould HJ (2003) Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol 33:1030–1040

    Article  PubMed  CAS  Google Scholar 

  • Karagiannis SN, Bracher MG, Hunt J, McCloskey N, Beavil RL, Beavil AJ, Fear DJ, Thompson RG, East N, Burke F, Moore RJ, Dombrowicz DD, Balkwill FR, Gould HJ (2007) IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol 179:2832–2843

    PubMed  CAS  Google Scholar 

  • Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12:6106–6115

    Article  PubMed  CAS  Google Scholar 

  • Khazaeli MB, Conry RM, LoBuglio AF (1994) Human immune response to monoclonal anti­bodies. J Immunother 15:42–52

    Article  CAS  Google Scholar 

  • Kipriyanov SM, Le GF (2004) Recent advances in the generation of bispecific antibodies for tumor immunotherapy. Curr Opin Drug Discov Devel 7:233–242

    PubMed  CAS  Google Scholar 

  • Knutson KL, Krco CJ, Erskine CL, Goodman K, Kelemen LE, Wettstein PJ, Low PS, Hartmann LC, Kalli KR (2006) T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol 24:4254–4261

    Article  PubMed  CAS  Google Scholar 

  • Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 246:495–497

    Article  Google Scholar 

  • Liu XY, Pop LM, Vitetta ES (2008) Engineering therapeutic monoclonal antibodies. Immunol Rev 222:9–27

    Article  PubMed  CAS  Google Scholar 

  • Lo KM, Lan Y, Lauder S, Zhang J, Brunkhorst B, Qin G, Verma R, Courtenay-Luck N, Gillies SD (2007) huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models. Cancer Immunol Immunother 56:447–457

    Article  PubMed  CAS  Google Scholar 

  • Lo AS, Zhu Q, Marasco WA (2008) Intracellular antibodies (intrabodies) and their therapeutic potential. Handb Exp Pharmacol 181:343–373

    Article  PubMed  CAS  Google Scholar 

  • Lonberg N (2005) Human antibodies from transgenic animals. Nat Biotechnol 23:1117–1125

    Article  PubMed  CAS  Google Scholar 

  • Luiten RM, Warnaar SO, Sanborn D, Lamers CH, Bolhuis RL, Litvinov SV, Zurawski VR Jr, Coney LR (1997) Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients. J Immunother 20:496–504

    Article  PubMed  CAS  Google Scholar 

  • Macor P, Mezzanzanica D, Cossetti C, Alberti P, Figini M, Canevari S, Tedesco F (2006) Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. Cancer Res 66:3876–3883

    Article  PubMed  CAS  Google Scholar 

  • Mantovani LT, Miotti S, Menard S, Canevari S, Raspagliesi F, Bottini C, Bottero F, Colnaghi MI (1994) Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Eur J Cancer 30A:363–369

    Article  PubMed  CAS  Google Scholar 

  • Marks JD, Griffiths AD, Malmqvist M, Clackson T, Bye JM, Winter G (1992) By-passing immunization: building high affinity human antibodies by chain shuffling. Biotechnology 10:779–783

    Article  PubMed  CAS  Google Scholar 

  • McCafferty J, Griffiths AD, Winter G, Chiswell DJ (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348:552–554

    Article  PubMed  CAS  Google Scholar 

  • Melani C, Figini M, Nicosia D, Luison E, Ramakrishna V, Casorati G, Parmiani G, Eshhar Z, Canevari S, Colombo MP (1998) Targeting of interleukin-2 to human ovarian carcinoma by fusion with a single-chain Fv anti-folate receptor antibody. Cancer Res 58:4146–4154

    PubMed  CAS  Google Scholar 

  • Mezzanzanica D, Garrido MA, Neblock DS, Daddona PE, Andrew SM, Zurawski VR Jr, Segal DM, Wunderlich JR (1991) Human T-lymphocytes targeted against an established human ovarian carcinoma with a bispecific F(ab’)2 antibody prolong host survival in a murine xenograft model. Cancer Res 51:5716–5721

    PubMed  CAS  Google Scholar 

  • Milstein C (1980) Monoclonal antibodies. Sci Am 243:66–74

    Article  PubMed  CAS  Google Scholar 

  • Miotti S, Canevari S, Ménard S, Mezzanzanica D, Porro G, Pupa SM, Regazzoni M, Tagliabue E, Colnaghi MI (1987) Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 39:297–303

    Article  PubMed  CAS  Google Scholar 

  • Miotti S, Negri DRM, Valota O, Calabrese M, Bolhuis RLH, Gratama JW, Colnaghi MI, Canevari S (1999) Level of anti-mouse antibody response induced by bispecific monoclonal antibody OC/TR in ovarian carcinoma patients is associated with longer survival. Int J Cancer 84:62–68

    Article  PubMed  CAS  Google Scholar 

  • Molloy AM, Quadros EV, Sequeira JM, Troendle JF, Scott JM, Kirke PN, Mills JL (2009) Lack of association between folate-receptor autoantibodies and neural-tube defects. N Engl J Med 361:152–160

    Article  PubMed  CAS  Google Scholar 

  • Molthoff CF, Prinssen HM, Kenemans P, Van Hof AC, Den Hollander W, Verheijen RH (1997) Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: a phase I study. Cancer 80:2712–2720

    Article  PubMed  CAS  Google Scholar 

  • Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 81:6851–6855

    Article  PubMed  CAS  Google Scholar 

  • Nagai T, Tanaka M, Tsuneyoshi Y, Xu B, Michie SA, Hasui K, Hirano H, Arita K, Matsuyama T (2009) Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor beta. Cancer Immunol Immunother 58:1577–1586

    Article  PubMed  CAS  Google Scholar 

  • Nagayoshi R, Nagai T, Matsushita K, Sato K, Sunahara N, Matsuda T, Nakamura T, Komiya S, Onda M, Matsuyama T (2005) Effectiveness of anti-folate receptor beta antibody conjugated with truncated Pseudomonas exotoxin in the targeting of rheumatoid arthritis synovial macrophages. Arthritis Rheum 52:2666–2675

    Article  PubMed  CAS  Google Scholar 

  • Nicolaides NC, Ebel W, Kline B, Chao Q, Routhier E, Sass PM, Grasso L (2005) Morphogenics as a tool for target discovery and drug development. Ann N Y Acad Sci 1059:86–96

    Article  PubMed  CAS  Google Scholar 

  • Niculescu-Duvaz I (2004) Technology evaluation: EMD-273063, EMD Lexigen. Curr Opin Mol Ther 6:559–566

    PubMed  CAS  Google Scholar 

  • Ottone F, Miotti S, Bottini C, Bagnoli M, Perego P, Colnaghi MI, Ménard S (1997) Relationship between folate binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines. Br J Cancer 76:77–82

    Article  PubMed  CAS  Google Scholar 

  • Paganelli G, Belloni C, Magnani P, Zito F, Pasini A, Sassi I, Meroni M, Mariani M, Vignali M, Siccardi AG, Fazio F (1992) Two-step tumor targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin. Eur J Nucl Med 19:322–329

    Article  PubMed  CAS  Google Scholar 

  • Parker LL, Do MT, Westwood JA, Wunderlich JR, Dudley ME, Rosenberg SA, Hwu P (2000) Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Hum Gene Ther 11:2377–2387

    Article  PubMed  CAS  Google Scholar 

  • Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ (2006) Immunotoxin therapy of cancer. Nat Rev Cancer 6:559–565

    Article  PubMed  CAS  Google Scholar 

  • Powers DB, Amersdorfer P, Poul M, Nielsen UB, Shalaby MR, Adams GP, Weiner LM, Marks JD (2001) Expression of single-chain Fv-Fc fusions in Pichia pastoris. J Immunol Methods 251:123–135

    Article  PubMed  CAS  Google Scholar 

  • Rettig WJ, Cordon-Cardo C, Koulos JP, Lewis JL Jr, Oettgen HF, Old LJ (1985) Cell surface antigens of human trophoblast and choriocarcinoma defined by monoclonal antibodies. Int J Cancer 35:469–475

    Article  PubMed  CAS  Google Scholar 

  • Rothenberg SP, da Costa MP, Sequeira JM, Cracco J, Roberts JL, Weedon J, Quadros EV (2004) Autoantibodies against folate receptors in women with a pregnancy complicated by a neural-tube defect. N Engl J Med 350:134–142

    Article  PubMed  CAS  Google Scholar 

  • Russell SJ, Peng KW (2009) Measles virus for cancer therapy. Curr Top Microbiol Immunol 330:213–241

    Article  PubMed  CAS  Google Scholar 

  • Salazar MD, Ratnam M (2007) The folate receptor: what does it promise in tissue-targeted ­therapeutics? Cancer Metastasis Rev 26:141–152

    Article  PubMed  CAS  Google Scholar 

  • Schmidt SR (2009) Fusion-proteins as biopharmaceuticals – applications and challenges. Curr Opin Drug Discov Devel 12:284–295

    PubMed  CAS  Google Scholar 

  • Smith AE, Pinkney M, Piggott NH, Calvert H, Milton ID, Lunec J (2007) A novel monoclonal antibody for detection of folate receptor alpha in paraffin-embedded tissues. Hybridoma (Larchmt) 26:281–288

    Article  CAS  Google Scholar 

  • Smith-Jones PM, Pandit-Taskar N, Cao W, O’Donoghue J, Philips MD, Carrasquillo J, Konner JA, Old LJ, Larson SM (2008) Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003. Nucl Med Biol 35:343–351

    Article  PubMed  CAS  Google Scholar 

  • Spannuth WA, Sood AK, Coleman RL (2010) FarletuzumAb in epithelial ovarian carcinoma. Expert, Opin Biol Ther

    Google Scholar 

  • Tatsuo H, Ono N, Tanaka K, Yanagi Y (2000) SLAM (CDw150) is a cellular receptor for measles virus. Nature 406:893–897

    Article  PubMed  CAS  Google Scholar 

  • Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M (1997) Overexpression of folate binding protein in ovarian cancers. Int J Cancer 74:193–198

    Article  PubMed  CAS  Google Scholar 

  • Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A (2004) An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10:871–875

    Article  PubMed  CAS  Google Scholar 

  • Valadon P, Garnett JD, Testa JE, Bauerle M, Oh P, Schnitzer JE (2006) Screening phage display libraries for organ-specific vascular immunotargeting in vivo. Proc Natl Acad Sci USA 103:407–412

    Article  PubMed  CAS  Google Scholar 

  • van Zanten-Przybysz I, Molthoff CF, Roos JC, Plaizier MA, Visser GW, Pijpers R, Kenemans P, Verheijen RH (2000) Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. J Nucl Med 41:1168–1176

    PubMed  Google Scholar 

  • Wagner K, Schulz P, Scholz A, Wiedenmann B, Menrad A (2008) The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer. Clin Cancer Res 14:4951–4960

    Article  PubMed  CAS  Google Scholar 

  • Willemsen RA, Debets R, Chames P, Bolhuis RL (2003) Genetic engineering of T cell specificity for immunotherapy of cancer. Hum Immunol 64:56–68

    Article  PubMed  CAS  Google Scholar 

  • Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K, Shitara K, Satoh M (2004) Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 87:614–622

    Article  PubMed  CAS  Google Scholar 

  • Yokota T, Milenic DE, Whitlow M, Schlom J (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52:3402–3408

    PubMed  CAS  Google Scholar 

  • Zacchetti A, Coliva A, Luison E, Seregni E, Bombardieri E, Giussani A, Figini M, Canevari S (2009) (177)Lu- labeled MOv18 as compared to (131)I- or (90)Y-labeled MOv18 has the ­better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts. Nucl Med Biol 36:759–770

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unit of Molecular Therapies, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

    Silvana Canevari

Authors
  1. Silvana Canevari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mariangela Figini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Silvana Canevari .

Editor information

Editors and Affiliations

  1. Section of Medicine, Institute of Cancer Research, Cotswold Road 15, Sutton, SM2 5NG, United Kingdom

    Ann L. Jackman

  2. Endocyte Inc., Kent Avenue 3000, West Lafayette, 47906, Indiana, USA

    Christopher P. Leamon

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Canevari, S., Figini, M. (2011). Anti-FR Antibody Generation and Engineering: Development of New Therapeutic Tools. In: Jackman, A., Leamon, C. (eds) Targeted Drug Strategies for Cancer and Inflammation. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-8417-3_8

Download citation

Publish with us

Policies and ethics

Search

Navigation